Klinische Wochenschrift

, Volume 65, Issue 14, pp 706–712 | Cite as

Zur Wirksamkeit von IFN-γ und IFN-α bei der Haarzellenleukämie

  • N. Niederle
  • C. Doberauer
  • O. Kloke
  • K. Höffken
  • C. G. Schmidt
Symposium Haarzelleukämie und ihre therapeutische Beeinflußbarkeit durch Interferone Erster Hannoverscher Interferon-Workshop, 1. Februar 1986

Zusammenfassung

6 Patienten mit einer Haarzellenleukämie wurden 3–35 Monate nach Splenektomie mit IFN-γ (4 × 106 E/m2/2. Tag sc) behandelt. Während einer Therapiedauer von 9–35 Wochen konnte bei keinem Patienten eine signifikante klinische oder hämatologische Befundbesserung erzielt werden. Nach einem therapiefreien Intervall von 0–13 Wochen erhielten alle Patienten IFN-α-2b (zunächst 4 × 106 E/m2/2. Tag, Erhaltungstherapie 1 × 106 E/2. Tag). Zum Zeitpunkt der Beendigung der jeweiligen IFN-α-2b-Gabe war bei 5 von 6 Patienten (1 Patient mit postthrombotischem Syndrom verstarb an einer Lungenembolie) eine deutliche Befundbesserung eingetreten. Nach einer Beobachtungszeit von jetzt 9–14 Monaten konnten 1 CR, 3 PR und 1 MR induziert werden. Die Nebenwirkungen beider Interferon-Präparationen unterschieden sich nicht signifikant.

Efficacy of gamma- and alpha-interferon in hairy-cell leukemia

Summary

Six patients with hairy-cell leukemia were treated with gamma-(IFN-γ) and alpha-(IFN-α-2b) interferon; 3–35 months following splenectomy, treatment was started with 4 × 106 U/m2 IFN-γ sc (iv) every second day for 9–35 weeks. Although the white blood cell counts decreased during therapy from 4.1–49 × 109/1 to 1.5–43 × 109/1, no hematological or clinical improvement was obtained. Subsequently (interval 0–13 weeks), IFN-α-2b was given at an initial dose of 4 × 106 U/m2 sc every second day to all patients. After a treatment period corresponding to that of IFN-γ administration, a significant hematological improvement was observed in five patients (one early death due to pulmonary embolism). At the last follow-up (9–14 months after start of treatment; maintenance therapy, 1 × 106 U every second day), these patients exhibited normal peripheral blood cell counts, and in bone marrow biopsy specimens a marked decrease of hairy cells was seen (1 CR, 3 PR, 1 MR). Adverse reactions including fever, headache, nausea, dryness of the mouth, myalgia, and fatigue did not significantly differ between the two interferon preparations. Whereas IFN-γ is unlikely to have any significant impact on the course of hairy cell leukemia, IFN-α-2b does result in improvement of hematological values and well-being in almost all patients.

Key words

Hairy-cell leukemia Interferon gamma Interferon alpha-2b 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Adolf GR (1985) Structure and effects of interferon-gamma. Oncology 42:(Suppl 1) 33–40Google Scholar
  2. 2.
    Beaupain R, Billard C, Falcoff E (1986) Effects of human recombinant interferon-α2, -β and -γ on growth and survival of human cancer nodules maintained in continuous organotypic culture. Eur J Cancer Clin Oncol 22:141–149Google Scholar
  3. 3.
    Blalock JE, Georgiades JA, Langford MP, Johnson HM (1980) Purified human immune interferon has more potent anticellular activity than fibroblast or leukocyte interferon. Cellular Immunol 49:390–394Google Scholar
  4. 4.
    Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood 13:609–630Google Scholar
  5. 5.
    Branca AA, Baglioni C (1981) Evidence that types I and II interferons have different receptors. Nature 294:768–770Google Scholar
  6. 6.
    Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY (1983) Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 131:1300–1305Google Scholar
  7. 7.
    Carrel S, Schmidt-Kessen A, Giuffrè L (1985) Recombinant interferon-γ can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol 15:118–123Google Scholar
  8. 8.
    Catovsky D (1977) Hairy-cell leukaemia and prolymphocytic leukaemia. Clin Haematol 6:245–268Google Scholar
  9. 9.
    DeMaeyer-Guignard J, Zawatzky R, Dandoy F, DeMaeyer E (1983) An X-linked locus influences early serum IFN level in the mouse. J Interferon Res 3:241–52Google Scholar
  10. 10.
    Denz H, Lechleitner M, Marth CH, Daxenbichler G, Gastl G, Braunsteiner H (1985) Effect of human recombinant alpha-2- and gamma-interferon on the growth of human cell lines from solid tumors and hematologic malignancies. J Interferon Res 5:147–157Google Scholar
  11. 11.
    Devos R, Cheroutre H, Taya Y, Degrave W, Van Heuverswyn H, Fiers W (1982) Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells. Nucleic Acids Res 10:2487–2501Google Scholar
  12. 12.
    Flandrin G, Sigaux F, Sebahoun G, Bouffette P (1984) Hairy cell leukemia: Clinical presentation and follow-up of 211 patients. Semin Oncol 11 (Suppl 2): 458–471Google Scholar
  13. 13.
    Gastl G, Aulitzky W, Margreiter R, Flener R, Van Camp B, Berneman Z, Peetermans M, Huber CH (1985) Recombinant α2 interferon for induction and maintenance of remission in hairy cell leukaemia. Br J Haematol 61:581–582Google Scholar
  14. 14.
    Golde DW, Stevens RH, Quan SG, Saxon A (1977) Immunoglobulin synthesis in hairy cell leukaemia. Br J Haematol 35:359–365Google Scholar
  15. 15.
    Golomb HM (1983) Hairy cell leukemia: Lessons learned in twenty-five years. J Clin Oncol 1:652–656Google Scholar
  16. 16.
    Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, Ratain M, Golde D, Vardiman J, Burke JS, Brady J, Bonnem E, Spiegel R (1986) Alpha-2 interferon therapy of hairy cell leukemia: A multicenter study of 64 patients. J Clin Oncol 4:900–905Google Scholar
  17. 17.
    Gray PW, Leung DW, Pennica D, Yelverton E, Najarian R, Simonsen CC, Derynck R, Sherwood PJ, Wallace DM, Berger SL, Levinson AD, Goeddel DV (1982) Expression of human immune interferon cDNA in E. coli and monkey cells. Nature 295:503–508Google Scholar
  18. 18.
    Gray PW, Goeddel DV (1982) Structure of the human immune interferon gene. Nature 298:859–863Google Scholar
  19. 19.
    Herrmann F, Cannistra SA, Levine H, Griffin JD (1985) Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med 162:1111–1116Google Scholar
  20. 20.
    Hofmann V, Scheel A, Schwarzmeier J, Talstad I, Varini M, Kaplan S, Sauter C, Fehr J (1985) Wirksamkeit von Interferon-α2 (E. coli) bei der Haarzell-Leukämie. Schweiz med Wochenschr 115:235–238Google Scholar
  21. 21.
    Jamshidi K, Swaim WR (1971) Bone marrow biopsy with unaltered architecture: a new biopsy device. J Lab Clin Med 77:335–342Google Scholar
  22. 22.
    Jansen J, den Ottolander GJ, Schuit HRE, Waayer JLM, Hijmans W (1984) Hairy cell leukemia: Its place among the chronic B cell leukemias. Semin Oncol 11:386–393Google Scholar
  23. 23.
    Jansen J, den Ottolander GJ, Holdrinet RSG, Tricot GJK, Hermans J (1984) Prognosis and therapy in hairy cell leukemia. Semin Oncol 11 (Suppl 2): 472–478Google Scholar
  24. 24.
    Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH (1948) The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer 1:634–656Google Scholar
  25. 25.
    Kirchner H (1984) Interferon Gamma. Progr clin Biochem Med 1:169–203Google Scholar
  26. 26.
    Kirchner H (1986) Das Interferonsystem unter besonderer Berücksichtigung des Gamma-Interferons. Dtsch med Wochenschr 111:64–70Google Scholar
  27. 27.
    Krown SE, Vadhan-Raj S, Nathan CF, Al-Katib A, Bhalla R, Sherwin SA, Oettgen HF (1985) Phase I trials of recombinant interferon gamma in cancer patients. The 1985 TNOISIR meeting on the interferon system, Abstracts: 42Google Scholar
  28. 28.
    Leibson HJ, Gefter M, Zlotnik A, Marrack P, Kappler JW (1984) Role of γ-interferon in antibody-producing responses. Nature 309:799–801Google Scholar
  29. 29.
    Liang C-M, Herren S, Fountoulakis M, Otto B, Hirschi M, Gutzwiller E, Gerlis L (1985) Analysis of antibody response in patients receiving recombinant Escherichia-coliderived human interferon-gamma. Clin Immunol Immunopathol 36:95–100Google Scholar
  30. 30.
    Marcucci F, Waller M, Kirchner H, Krammer P (1981) Production of immune interferon by murine T-cell clones from long-term cultures. Nature 291:79–81Google Scholar
  31. 31.
    Melo JV, San Miguel JF, Moss VE, Catovsky D (1984) The membrane phenotype of hairy cell leukemia: A study with monoclonal antibodies. Semin Oncol 11, 381–385Google Scholar
  32. 32.
    Metz U, Kurschel E, Niederle N, Oehl S (1985) Urinary enzymes in the detection of the nephrotoxic potential of recombinant human-α-interferon. In: Bach PH, Lock EA (eds): Renal heterogeneity and target cell toxicity. John Wiley & Sons, Chichester-New York-Brisbane-Toronto-Singapore: 267–270Google Scholar
  33. 33.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214Google Scholar
  34. 34.
    Nakamura M, Manser T, Pearson GDN, Daley MJ, Gefter ML (1984) Effect of IFN-γ on the immune response in vivo and on gene expression in vitro. Nature 307:381–382Google Scholar
  35. 35.
    Niederle N, Kurschel E, Schütte J, Krischke W, Schmidt CG, Gerlis L, Gutzwiller E (1984) Phase I study of recombinant human interferon gamma (rIFN-γ) in patients with advanced cancer. In: Kirchner H, Schellekens H (eds): The Biology of the Interferon System 1984. Elsevier Science Publishers, Amsterdam: 509–515Google Scholar
  36. 36.
    Niederle N, Kloke O, Nowrousian MR, Kruse H, Schmidt CG (1986) Efficacy of gamma and alpha interferon in the treatment of hairy cell leukemia. J Cancer Res clin Oncol 111 (Suppl):40 (Int 04)Google Scholar
  37. 37.
    Paganelli KA, Evans SS, Han T, Ozer H (1986) B cell growth factor-induced proliferation of hairy cell lymphocytes and inhibition by type I interferon in vitro. Blood 67:937–942Google Scholar
  38. 38.
    Porzsolt F, Thomä J, Unsöld M, Wolf W, Obert HJ, Kubanek B, Heimpel H (1985) Platelet-adjusted IFN dosage in the treatment of advanced hairy cell leukemia. Blut 51:73–82Google Scholar
  39. 39.
    Porzsolt F, Janik R, Heil G, Brudler O, Raghavachar A, Scholz S, Papendick U, Heimpel H (1986) Deficient IFN-α production in hairy cell leukemia. Blut 52:185–190Google Scholar
  40. 40.
    Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310:15–18Google Scholar
  41. 41.
    Quesada JR, Hersh EM, Gutterman JU (1985) Therapy of hairy cell leukemia with interferons. The 1985 TNO-ISIR meeting on the interferon system, Abstracts:43Google Scholar
  42. 42.
    Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985) Treatment of hairy cell leukemia with recombinant alpha2 interferon. Blood 65:644–648Google Scholar
  43. 43.
    Rubin BY, Gupta SL (1980) Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci USA 77:5928–5932Google Scholar
  44. 44.
    Sidman CL, Marshall JD, Shultz LD, Gray PW, Johnson HM (1984) γ-Interferon is one of several direct B cell-maturing lymphokines. Nature 309:801–804Google Scholar
  45. 45.
    Twentyman PR, Workman P, Whright KA, Bleehen NM (1985) The effects of α and γ interferons on human lung cancer cells grown in vitro or as xenografts in nude mice. Br J Cancer 52:21–29Google Scholar
  46. 46.
    Valle MJ, Jordan GW, Haahr S, Merigan TC (1975) Characteristics of immune interferon produced by human lymphocyte cultures compared to other human interferons. J Immunol 115:230–233Google Scholar
  47. 47.
    Wheelock EF (1967) Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin. Science 149:310–311Google Scholar
  48. 48.
    Worman CP, Catovsky D, Bevan PC, Camba L, Joyner M, Green PJ, Williams HJH, Bottomley JM, Gordon-Smith EC, Cawley JC (1985) Interferon is effective in hairy-cell leukaemia. Br J Haematol 60:759–763Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • N. Niederle
    • 1
  • C. Doberauer
    • 1
  • O. Kloke
    • 1
  • K. Höffken
    • 1
  • C. G. Schmidt
    • 1
  1. 1.Innere Universitätsklinik und Poliklinik (Tumorforschung)Westdeutsches TumorzentrumEssen

Personalised recommendations